Bio-Thera Solutions Expands its Partnership with Pharmapark for BAT2306 (Biosimilar, Cosentyx) Across Russia and Other Countries
Shots:
- Pharmapark will hold exclusive distribution, and marketing rights & filing for BAT2306 (Secukinumab bsm) which has finished the P-I & P-III study globally and plans to submit applications for approval to the NMPA, EMA & FDA.
- Under the terms of the agreement, BAT2306 will be developed & supplied by Bio-Thera at its Guangzhou, China facility, and Pharmapark will be responsible for the regulatory & commercial activities across Russia and CIS countries
- This is a third expansion of the existing agreement between the two companies which includes BAT2506 (Biosimilar, Golimumab) also includes BAT2206 (Biosimilar, Ustekinumab)
Ref: Bio-Thera Solutions and Pharmapark | Image: Bio-Thera Solutions and Pharmapark
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
